Hemab Therapeutics (COAG) news
Recent news
Hemab Therapeutics - Q2 net loss $24.20 mln, or $0.80 per share
AInvest Wire · Aug 11, 2026Jefferies raises target price to $47 from $39 for HEMAB Therapeutics Holdings Inc
Jefferies LLC has raised its price target for Hemab Therapeutics Holdings Inc (Nasdaq: COAG) to $47 from $39, reflecting updated expectations based on recent developments in the company’s clinical pipeline and market performance. Hemab, a clinical-stage biotechnology firm focused on blood…
AInvest Wire · Jul 13, 2026Hemab Therapeutics Holdings, Inc.: H.C. Wainwright initiates coverage with buy rating and target price $40
H.C. Wainwright has initiated coverage on Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG) with a "Buy" rating and a target price of $40 per share. Hemab, a clinical-stage biotechnology company, is focused on developing novel therapies for patients with serious bleeding and thrombotic disorders,…
AInvest Wire · Jun 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.